Skip to main content

Recursion Pharmaceuticals, Inc 10-Q for FY2026 Q3

Recursion Pharmaceuticals, Inc. (RXRX)

10-Q 2026-11-02 For: 2026-09-30
View Original
Added on November 02, 2026

About this 10-Q

Recursion Pharmaceuticals, Inc filed this 10-Q on November 2, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Recursion reported further positive data from its Phase 1b/2 TUPELO trial of REC-4881 in FAP. After 12 weeks, 87% of patients (13 of 15) had reduced total polyp burden, with a 47% median reduction. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$18.55M
up 258.5% from $5.18M a year earlier
Net loss
$119.04M
compared with a net loss of $162.25M a year earlier
Diluted EPS
-$0.22
compared with -$0.36 a year earlier